WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 401691
CAS#: 1046859-34-0
Description: PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In addition, AKT degradation in PBLs may serve as a biomarker in clinical development.
MedKoo Cat#: 401691
Name: PF-4942847
CAS#: 1046859-34-0
Chemical Formula: C20H18Cl2F3N7O2
Exact Mass: 515.08511
Molecular Weight: 516.3
Elemental Analysis: C, 46.53; H, 3.51; Cl, 13.73; F, 11.04; N, 18.99; O, 6.20
PF-4942847 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: PF4942847; PF-4942847; PF 4942847; PF04942847
IUPAC/Chemical Name: 2-Amino-4-[2,4-dichloro-6-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]-5,7-dihydro-N-(2,2,2-trifluoroethyl)-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
InChi Key: GVSHPPIHCUEEAH-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H18Cl2F3N7O2/c21-11-6-13(22)16(15(7-11)34-5-4-32-3-1-2-28-32)17-12-8-31(9-14(12)29-18(26)30-17)19(33)27-10-20(23,24)25/h1-3,6-7H,4-5,8-10H2,(H,27,33)(H2,26,29,30)
SMILES Code: O=C(NCC(F)(F)F)N1CC2=NC(N)=NC(C3=C(C=C(C=C3Cl)Cl)OCCN4N=CC=C4)=C2C1
The following data is based on the product molecular weight 516.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Mehta PP, Whalen P, Baxi SM, Kung PP, Yamazaki S, Yin MJ. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90. Clin Cancer Res. 2011 Aug 15;17(16):5432-42. doi: 10.1158/1078-0432.CCR-11-0592. Epub 2011 Jun 29. PubMed PMID: 21715568.